HC Wainwright Reiterates “Buy” Rating for UroGen Pharma (NASDAQ:URGN)

UroGen Pharma (NASDAQ:URGN)‘s stock had its “buy” rating restated by analysts at HC Wainwright in a research report issued to clients and investors on Monday, Benzinga reports. They presently have a $54.00 price objective on the stock. HC Wainwright’s price objective suggests a potential upside of 277.62% from the stock’s previous close.

Separately, Oppenheimer reduced their target price on UroGen Pharma from $35.00 to $34.00 and set an “outperform” rating on the stock in a report on Friday, March 15th.

UroGen Pharma Stock Performance

UroGen Pharma stock opened at $14.30 on Monday. The business’s 50-day simple moving average is $15.30 and its 200-day simple moving average is $14.68. The firm has a market capitalization of $335.34 million, a PE ratio of -3.83 and a beta of 1.09. UroGen Pharma has a 52 week low of $8.69 and a 52 week high of $24.13.

UroGen Pharma (NASDAQ:URGN) last released its quarterly earnings data on Thursday, March 14th. The company reported ($0.72) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.05). The business had revenue of $23.53 million during the quarter, compared to the consensus estimate of $22.30 million. Research analysts forecast that UroGen Pharma will post -3.59 earnings per share for the current year.

Insiders Place Their Bets

In related news, insider Mark Schoenberg sold 12,000 shares of the stock in a transaction that occurred on Monday, March 18th. The shares were sold at an average price of $14.05, for a total value of $168,600.00. Following the transaction, the insider now directly owns 139,437 shares in the company, valued at $1,959,089.85. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 11.13% of the company’s stock.

Institutional Trading of UroGen Pharma

Institutional investors and hedge funds have recently modified their holdings of the stock. RTW Investments LP grew its holdings in shares of UroGen Pharma by 101.4% in the 4th quarter. RTW Investments LP now owns 1,726,808 shares of the company’s stock valued at $25,902,000 after buying an additional 869,344 shares during the period. RA Capital Management L.P. bought a new position in UroGen Pharma in the third quarter valued at approximately $20,787,000. Silverarc Capital Management LLC bought a new position in UroGen Pharma in the third quarter valued at approximately $7,129,000. Laurion Capital Management LP lifted its stake in UroGen Pharma by 3.1% in the third quarter. Laurion Capital Management LP now owns 380,600 shares of the company’s stock valued at $5,332,000 after buying an additional 11,495 shares in the last quarter. Finally, Superstring Capital Management LP bought a new position in UroGen Pharma in the fourth quarter valued at approximately $3,831,000. 91.29% of the stock is owned by institutional investors.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.